

Mono-Methyl-Histone H2B (Lys12) Rabbit pAb

Mono-Methyl-Histone H2B (Lys12) Rabbit pAb

Catalog # AP94503

Product Information

Application	WB
Host	Rabbit
Clonality	Polyclonal
Calculated MW	14 KDa
Physical State	Liquid
Isotype	IgG
Purity	Antigen affinity purification

Buffer 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Important Note This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.

Background Descriptions 组蛋白翻译后修饰（PTMs）是表观遗传学调控染色质结构的关键机制，被称为“组蛋白密码”。组蛋白上的翻译后修饰包括乙酰化，甲基化，磷酸化和近年发现的一些新型酰化修饰。这些组蛋白修饰直接影响染色质和转录因子或其他表观调控子的结合，改变基因组的稳定性和基因转录等。组蛋白甲基化通常发生在核心组蛋白的赖氨酸和精氨酸残基。组蛋白甲基化既可以促进也可以抑制基因转录，这取决于组蛋白甲基化是发生在赖氨酸还是发生在精氨酸上以及甲基化基团的个数（赖氨酸可以发生一、二、三甲基化，精氨酸可发生单、对称与非对称二甲化）。组蛋白赖氨酸甲基化通常发生在组蛋白H3第4，9，27，36，79和组蛋白H4的第20位赖氨酸上；精氨酸甲基化通常发生在组蛋白H3的第2，8，17，26和组蛋白H4第3位精氨酸上。蛋白甲基化酶（HMT）和组蛋白去甲基化酶（HDM）是甲基化修饰主要的调控因子。


Additional Information

Dilution	WB=1:500-1:2000
Format	0.01M TBS(pH7.4) with 1% BSA, 0.09% (W/V) sodium azide and 50% Glyce
Storage	Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.


Background

This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.

Images



Blocking buffer: 5% NFDM/TBST Primary ab dilution: 1:2000 Primary ab incubation condition: 2 hours at room temperature Secondary ab: Goat Anti-Rabbit IgG H&L (HRP) Lysate: HeLa, H1299, 293T, C2C12 Protein loading quantity: 20 µg Exposure time: 60 s Predicted MW: 14 kDa Observed MW: 14 kDa



Blocking buffer: 5% NFDM/TBST Primary ab dilution: 1:2000 Primary ab incubation condition: 2 hours at room temperature Secondary ab: Goat Anti-Rabbit IgG H&L (HRP) Lysate: Mouse spleen Protein loading quantity: 20 µg Exposure time: 60 s Predicted MW: 14 kDa Observed MW: 14 kDa

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.